142 related articles for article (PubMed ID: 26097419)
41. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [
Hooijman EL; Ntihabose CM; Reuvers TGA; Nonnekens J; Aalbersberg EA; van de Merbel JRJP; Huijmans JE; Koolen SLW; Hendrikx JJMA; de Blois E
EJNMMI Radiopharm Chem; 2022 Nov; 7(1):29. PubMed ID: 36333648
[TBL] [Abstract][Full Text] [Related]
42. Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Kumar C; Vats K; Lohar SP; Korde A; Samuel G
Cancer Biother Radiopharm; 2014 Oct; 29(8):317-22. PubMed ID: 25226352
[TBL] [Abstract][Full Text] [Related]
43. ¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay.
Balter H; Victoria T; Mariella T; Javier G; Rodolfo F; Andrea P; Graciela R; Juan H; Eugenia de M; Patricia O
Curr Radiopharm; 2016; 9(1):85-93. PubMed ID: 25771367
[TBL] [Abstract][Full Text] [Related]
44. A computer assisted comparison of 99Tcm-methylene-diphosphonate and 99Tcm-pyrophosphate bone imaging.
Büll U; Pfeifer JP; Niendorf HP; Tongendorff J
Br J Radiol; 1977 Sep; 50(597):629-36. PubMed ID: 198055
[TBL] [Abstract][Full Text] [Related]
45. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR
Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297
[TBL] [Abstract][Full Text] [Related]
46. Theranostic Applications of Lutetium-177 in Radionuclide Therapy.
Das T; Banerjee S
Curr Radiopharm; 2016; 9(1):94-101. PubMed ID: 25771364
[TBL] [Abstract][Full Text] [Related]
47. Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis.
Trujillo-Nolasco RM; Morales-Avila E; Ocampo-García BE; Ferro-Flores G; Gibbens-Bandala BV; Escudero-Castellanos A; Isaac-Olive K
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109766. PubMed ID: 31349410
[TBL] [Abstract][Full Text] [Related]
48.
Alavi M; Khajeh-Rahimi F; Yousefnia H; Mohammadianpanah M; Zolghadri S; Bahrami-Samani A; Ghannadi-Maragheh M
Cancer Biother Radiopharm; 2019 Jun; 34(5):280-287. PubMed ID: 30977670
[No Abstract] [Full Text] [Related]
49. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
50. Lu-177-Labeled Zirconia Particles for Radiation Synovectomy.
Polyak A; Nagy LN; Drotár E; Dabasi G; Jóba RP; Pöstényi Z; Mikolajczak R; Bóta A; Balogh L
Cancer Biother Radiopharm; 2015 Dec; 30(10):433-8. PubMed ID: 26683134
[TBL] [Abstract][Full Text] [Related]
51. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
[TBL] [Abstract][Full Text] [Related]
52. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
53. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
54. Formulation and characterization of lutetium-177-labeled stannous (tin) colloid for radiosynovectomy.
Arora G; Singh M; Jha P; Tripathy S; Bal C; Mukherjee A; Shamim SA
Nucl Med Commun; 2017 Jul; 38(7):587-592. PubMed ID: 28538080
[TBL] [Abstract][Full Text] [Related]
55. A "mix-and-use" approach for formulation of human clinical doses of
Chakraborty S; Vimalnath KV; Rajeswari A; Chakravarty R; Sarma HD; Radhakrishnan E; Kamaleshwaran K; Shinto AS; Dash A
J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391
[TBL] [Abstract][Full Text] [Related]
56. Preparation and evaluation of a new radiopharmaceutical for radiosynovectomy, 111Ag-labelled hydroxyapatite (HA) particles.
Chattopadhyay S; Vimalnath KV; Saha S; Korde A; Sarma HD; Pal S; Das MK
Appl Radiat Isot; 2008 Mar; 66(3):334-9. PubMed ID: 17951062
[TBL] [Abstract][Full Text] [Related]
57. (175)Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals.
Safarzadeh L
Indian J Nucl Med; 2014 Jul; 29(3):135-9. PubMed ID: 25210277
[TBL] [Abstract][Full Text] [Related]
58. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation.
Chakraborty S; Das T; Unni PR; Sarma HD; Samuel G; Banerjee S; Venkatesh M; Ramamoorthy N; Pillai MR
Nucl Med Commun; 2002 Jan; 23(1):67-74. PubMed ID: 11748440
[TBL] [Abstract][Full Text] [Related]
59. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
60. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.
Salek N; Shamsaei M; Ghannadi Maragheh M; Shirvani Arani S; Bahrami Samani A
J Appl Clin Med Phys; 2016 Nov; 17(6):128-139. PubMed ID: 27929488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
